Heilongjiang ZBD Pharmaceutical Co., Ltd. Stock

Equities

603567

CNE100002219

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
12.43 CNY +0.32% Intraday chart for Heilongjiang ZBD Pharmaceutical Co., Ltd. +2.64% +2.22%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 4.21B 583M Sales 2023 3.14B 435M Capitalization 11.42B 1.58B
Net income 2022 185M 25.61M Net income 2023 473M 65.47M EV / Sales 2022 3.29 x
Net Debt 2022 1.86B 258M Net Debt 2023 1.7B 235M EV / Sales 2023 4.17 x
P/E ratio 2022
64.8 x
P/E ratio 2023
24.2 x
Employees 2,760
Yield 2022
0.22%
Yield 2023
-
Free-Float 23.66%
More Fundamentals * Assessed data
Dynamic Chart
China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ZBD Pharma Gets Nod for Tofacitinib Citrate Tablets MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
HeiLongJiang ZBD Pharma Registers Osteoarthritis Drug MT
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to S&P Global BMI Index CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to FTSE All-World Index CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 10, 2022 has closed with 2,560,300 shares, representing 0.27% for CNY 30 million. CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022. CI
More news
1 day+0.32%
1 week+2.64%
Current month+2.64%
1 month+11.48%
3 months+13.21%
6 months-8.80%
Current year+2.22%
More quotes
1 week
12.14
Extreme 12.14
12.56
1 month
10.45
Extreme 10.45
12.56
Current year
8.89
Extreme 8.89
12.56
1 year
8.89
Extreme 8.89
17.87
3 years
8.89
Extreme 8.89
19.22
5 years
8.89
Extreme 8.89
19.22
10 years
8.89
Extreme 8.89
60.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 16-12-31
Founder 61 96-10-27
Director of Finance/CFO 43 19-09-25
Members of the board TitleAgeSince
Director/Board Member 60 19-05-16
Founder 61 96-10-27
Chairman 51 02-12-31
More insiders
Date Price Change Volume
24-05-08 12.43 +0.32% 8,708,700
24-05-07 12.39 +0.49% 7,310,001
24-05-06 12.33 +1.82% 10,637,560
24-04-30 12.11 +0.92% 10,646,000

End-of-day quote Shanghai S.E., May 07, 2024

More quotes
HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research and development, manufacture and sales of Chinese patent medicine. The Company's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The Company distributes its products under the brand named Zhenbaodao.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603567 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW